Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. In this 52-week, double-blin...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American Academy of Dermatology Vol. 73; no. 3; pp. 400 - 409
Main Authors:	Thaçi, Diamant, Blauvelt, Andrew, Reich, Kristian, Tsai, Tsen-Fang, Vanaclocha, Francisco, Kingo, Külli, Ziv, Michael, Pinter, Andreas, Hugot, Sophie, You, Ruquan, Milutinovic, Marina
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.09.2015
Subjects:	90% or more improvement in baseline Psoriasis Area and Severity Index Adult Analysis of Variance Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects clear or almost clear skin clinical trial Dermatology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies head to head Humans Injections, Subcutaneous Male Maximum Tolerated Dose Middle Aged plaque psoriasis Psoriasis - diagnosis Psoriasis - drug therapy Reference Values Risk Assessment secukinumab Severity of Illness Index superiority Treatment Outcome ustekinumab Ustekinumab - administration & dosage Ustekinumab - adverse effects clinical trial DLQI PASI 90 IGA PASI IL superiority AE IGA mod 2011 MedDRA secukinumab PASI 75 clear or almost clear skin TNF head to head PASI 100 ustekinumab SAE plaque psoriasis HRQoL 90% or more improvement in baseline Psoriasis Area and Severity Index investigator global assessment 2011 modified version Psoriasis Area and Severity Index Medical Dictionary for Regulatory Activities serious adverse event 75% or more improvement from baseline Psoriasis Area and Severity Index score interleukin 100% improvement from baseline Psoriasis Area and Severity Index score adverse event health-related quality of life 90% or more improvement from baseline Psoriasis Area and Severity Index score investigator global assessment tumor necrosis factor Dermatology Life Quality Index
ISSN:	0190-9622, 1097-6787
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!